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Abstract.
Background: Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by the degeneration of alpha
motor neurons in the spinal cord, leading to muscular atrophy. SMA is caused by deletions or mutations in the survival
motor neuron 1 gene (SMN1). In humans, a nearly identical copy gene, SMN2, is present. Because SMN2 has been shown to
decrease disease severity in a dose-dependent manner, SMN2 copy number is predictive of disease severity.
Objective: To develop a treatment algorithm for SMA-positive infants identified through newborn screening based upon
SMN2 copy number.
Methods: A working group comprised of 15 SMA experts participated in a modified Delphi process, moderated by a neutral
third-party expert, to develop treatment guidelines.
Results: The overarching recommendation is that all infants with two or three copies of SMN2 should receive immediate
treatment (n = 13). For those infants in which immediate treatment is not recommended, guidelines were developed that
outline the timing and appropriate screens and tests to be used to determine the timing of treatment initiation.
Conclusions: The identification SMA affected infants via newborn screening presents an unprecedented opportunity for
achievement of maximal therapeutic benefit through the administration of treatment pre-symptomatically. The recommen-
dations provided here are intended to help formulate treatment guidelines for infants who test positive during the newborn
screening process.
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INTRODUCTION
SMA clinical features and spectrum of severity
Spinal muscular atrophy (SMA) is an autosomal
recessive disorder predominately caused by bi-allelic
deletion of the survival motor neuron 1 (SMN1) gene.
It is characterized by dysfunction and then loss of the
alpha motor neurons in the spinal cord that causes
progressive muscle atrophy and weakness [1, 2]. A
large study in a broad cohort from the United States
identified an overall carrier frequency of 1 in 54, with
a calculated incidence of 1 in 11,000 [3]. Historically,
SMA has been the leading monogenic cause of death
in infancy, but there is reason for hope that this will
greatly change with widespread early administration
of newly approved disease modifying therapies.
SMA manifests across a continuous gradient of
phenotype severity, separated by functional “type”
based on age of onset and maximum motor milestones
achieved [4]. Individuals with onset of weakness in
the first six months of infancy who never achieve an
ability to sit independently, once known as “Werdnig-
Hoffmann disease” but now classified as having
“SMA type 1”, constitute approximately 60% of all
individuals with SMA [2, 5, 6–10]. Approximately
30% of patients are diagnosed with “SMA type 2”.
These patients present with weakness recognized in
later infancy and achieve the ability to sit, but not
walk, independently. Those able to walk are grouped
under the “SMA type 3” or “Kugelberg-Welander”
label and constitute approximately 10% of the patient
population. Some clinicians include outlier groups
labeled as “SMA type 0”, referring to fetal onset with
severe weakness, joint contractures, and respiratory
compromise presenting at birth; and “SMA type 4”
denoting a small group who first show weakness in
adult years. Across the range of SMA, at all levels of
severity, there is a common path of relatively greater
progression of weakness, or departure from a normal
pattern of developmental gain of milestones, followed
thereafter by a slower plateau of relative stability with
very slow worsening.
Approximately 95% of all individuals with SMA,
at all levels of phenotypic severity, have a homozy-
gous SMN1 gene deletion, detection of which serves
as the primary diagnostic assay for the disorder. All
individuals with SMA have a variable copy num-
ber SMN2, a paralog of SMN1, that produces low,
but essential levels of SMN protein. Copy number
of SMN2 correlates inversely with SMA phenotype
severity, as greater SMN2 copy number is associated
with milder phenotypic presentation [11]. At the most
severe end, a single copy of SMN2 is associated with
very severe weakness and a limited duration of sur-
vival after birth with SMA type 0 [12, 13]. In one
large German study, 80% of those with SMA type
1 have two or fewer copies of SMN2, 82% of those
with SMA type 2 have three copies ofSMN2, and 96%
of those with SMA type 3 have three or four copies
of SMN2. This relationship of phenotype to geno-
type thus enables prediction of SMA type from the
SMN2 copy number before the onset of symptoms.
Infants found to have two or three copies of SMN2 are
highly likely to manifest SMA type 1 or 2, which are
associated with high early mortality and substantial
morbidity. Conversely, those with four or more copies
of SMN2 are extremely unlikely (<0.5%, or 1:298 in
combined cohorts; [12–15]) to present with the most
severe SMA type 1. In addition, all of these stud-
ies predict that less than 10% of SMA cases would
first present in children older than three years, and
these would typically be classified as having SMA
type 3. Thus, identification of homozygous deletion
ofSMN1 combined with determination ofSMN2 copy
number is a powerful predictor of disease and iden-
tifies a group who would benefit substantially from
new and emerging therapies.
SMA treatments and therapies
SMA directly causes muscle weakness, leading to
numerous downstream complications, many of which
are amenable to supportive care that has been outlined
in standard-of-care consortia [5, 16, 17]. Respiratory
treatment with bi-level positive airway pressure sup-
port when appropriate, orthopedic management of
scoliosis and other deformities, and nutritional sup-
port have made meaningful differences in clinical
outcome [11, 16–18]. SMA has also been advantaged
by a robust drug development pipeline involving sev-
eral different lines of specific therapeutic strategies
evolving over the last decade. One therapy called
nusinersen, directed at improving functional SMN
protein expression by altering SMN2 transcript splic-
ing using an antisense oligonucleotide approach, was
recently approved by the Food and Drug Administra-
tion (FDA) and is now commercially available. Other
approaches to therapy at the level of increasing SMN
protein levels, including a gene transfer approach
using an AAV9 vector [19] or small molecule mod-
ification of SMN2 splicing [20], are in promising
clinical trials. Additional approaches, including puta-
tive neuroprotective agents and therapies intending
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to increase muscle function directly, are also in
development [20].
Rationale for early intervention
Thus far, both clinical and preclinical data indi-
cate that early treatment will be critical to modulate
the rapid and progressive degeneration seen in SMA,
especially in type 1. There is strong evidence that
the irreversible loss of motor neurons in humans with
SMA type 1 begins early in the perinatal period, with
severe denervation in the first three months and loss
of more than 90% of motor units within six months
of age [11]. Furthermore, preclinical studies looking
at the timing of drug delivery in severe mouse mod-
els of SMA consistently show that the best results
occur when drugs are given as early as possible,
before significant motor weakness or loss is present
[21, 22]. Despite such evidence, diagnostic delay is
very common in SMA. A recent systematic litera-
ture search covering 21 reports for studies published
between 2000 and 2014 showed that the mean ages
of symptom onset were 2.5, 8.3, and 39.0 months
for SMA types 1, 2, and 3 respectively, whereas
the weighted mean ages of confirmed SMA diagno-
sis were 6.3, 20.7, and 50.3 months for types 1, 2,
and 3, respectively [23]. Because of these diagnostic
delays and the lack of newborn screening (NBS) for
SMA, most patients have progressed past the point
where maximal benefit is achievable before thera-
peutic interventions occur. Given that most affected
individuals seek treatment when diagnosed, NBS has
the potential to increase the benefit of these therapies
without increasing the cost of therapy. Furthermore,
NBS may substantially decrease the cost of support
needed to help those with functional impairment.
The role of timing in successful drug interven-
tion is also apparent from two Biogen-sponsored
clinical trials testing nusinersen in symptomatic and
pre-symptomatic infants. The ENDEAR trial was
a randomized, placebo-controlled clinical trial that
included 121 subjects with infantile-onset SMA and
two copies of SMN2 who were diagnosed before 6
months of age and who were less than 7 months
old at the time of their first dose. In the final analy-
sis, 51% of subjects treated with nusinersen achieved
improvement in motor milestones, whereas none of
the control subjects did (p < 0.001). Additionally,
only 32% of infants with a disease duration of more
than 12 weeks responded positively on the Hammer-
smith Infant Neurological Examination (HINE) [24]
motor milestone, compared to 75% of infants with
disease duration of 12 weeks or less. Moreover, nusin-
ersen demonstrated a statistically significant 47%
reduction in the risk of death or permanent ventilation
(p = 0.005) and had a favorable safety profile [25].
In contrast, the NURTURE trial is an ongoing open-
label clinical trial that enrolled pre-symptomatic,
genetically diagnosed infants with SMA having two
or three copies of SMN2 who were less than 6 weeks
of age at first dose. Interim analysis showed that 100%
of the infants were still alive and did not require inva-
sive ventilation at all or non-invasive ventilation for
greater than 6 hours per day continuously for more
than 7 days [26]. In comparison, the total mean HINE
score improvement was substantially higher in the
pre-symptomatic subjects of NURTURE compared
to the symptomatic subjects of ENDEAR. Overall,
greater attainment of specific motor milestones was
achieved with pre-symptomatic treatment compared
to symptomatic treatment, and many of these sub-
jects have achieved motor skills at a developmentally
appropriate age and have remained free of the need for
ventilation or feeding support (Table 1). The NUR-
TURE study results are a strong indicator of the
importance of NBS in achieving maximal efficacy
with SMN enhancers in treating SMA.
Newborn screening assays
As described above, to achieve maximal therapeu-
tic benefit, early identification of affected infants in
the pre-symptomatic period is critical. Therefore, the
need for reliable and well validated newborn screen-
ing assays is paramount.
An SMN1 assay has been developed that utilizes
a modified, multiplexed real-time polymerase chain
reaction (PCR) to detect the presence of SMN1 from
a dried blood spot. Initial results show that the assay
identified SMN1 exon 7 deletions in all SMA-affected
patients, while all unaffected individuals showed the
presence of exon 7. This molecular assay is inexpen-
sive, as it can be multiplexed at minimal additional
cost to a broadly accepted assay for severe combined
immunodeficiency (SCID) [27]. There have been two
pilot studies using this or similar assays in Taiwan
and New York State. The Taiwan pilot study detected
homozygous deletions in SMN1 intron 7, while the
New York state pilot study is detecting homozygous
and heterozygous (carrier) deletions in SMN1 exon 7.
From November 2014 to September 2016, a total of
120,267 infants had been tested in the Taiwan pilot
study. From January to December 2016, a total of
3,264 infants were tested at three hospitals in New
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Table 1
Summary of motor milestone achievements of infants receiving nusinersen in ENDEAR versus NURTURE clinical trials
Milestone Total number of infants achieving milestone, n/N (%)
ENDEARa NURTUREb
(Symptomatic patients; N = 73) (Pre-symptomatic patients; N = 13)
Head control (full) 16/73 (22) 5/9 (55)
Sitting (independent: stable, pivot) 6/73 (8) 6/13 (46)
Standing (stands with support, unaided) 1/73 (1) 4/13 (31)
Walking (cruising, walking) 0/73 (0) 2/13 (15)
n = number of patients with milestone; N = number of patients analyzed for that milestone. a[25]. b[26]. Note: Only infants with
two copies of SMN2 were included in this table (no three-copy SMN2 patients were included from the NURTURE trial). All
infants who enrolled in ENDEAR had two copies of SMN2. Note: The ENDEAR interim was performed when 51 subjects who
received nusinersen had the opportunity to be treated and observed for at least 183 days and up to 394 days. The NURTURE
interim analysis data cutoff date was October 31, 2016.
York State [28]. In both studies, the assays have
shown 100% positive predictive value using DNA
extracted from dried blood spot punches.
A second, commercial real-time PCR assay has
been developed by PerkinElmer that detects homozy-
gous and heterozygous deletions in SMN1 exon 7 and
SMN2 copy number from a dried blood spot punch.
This assay was also designed to be multiplexed with
the SCID assay. An ongoing study is currently being
conducted toscreenover3,000samples,withanalyses
thus far showing 100% positive predictive value [29].
Researchanddevelopment studiesarecurrentlyongo-
ing for this assay, and pilot studies are being planned.
SMA Recently suggested as a condition on the
recommended uniform screening panel
In order for new conditions to be added to the RUSP
for newborns, several elements are required. These
include a body of evidence on the condition itself
and treatment options supported by evidence-based
information, including validation of a laboratory test,
widely available confirmatory testing with a sensi-
tive and specific diagnostic test, and a prospective
population-based pilot study. For SMA, there is now
strong natural history data that indicate typical pro-
gression as well as an approved treatment that demon-
strates higher therapeutic value when administered
in pre-symptomatic infants. Adequate pilot screen-
ing data from state public labs is available utilizing
an inexpensive and reliable diagnostic test for broad-
scale use. The SMN1 deletion testing has been shown
to be highly sensitive and specific, and the SMN2
copy determination will provide important prognos-
tic information. In February 2018, the Advisory
Committee on Heritable Disorders in Newborns and
Children (ACHDNC) voted to recommend SMA for
addition to the RUSP. The recommendation now goes
to the Health and Human Services secretary for final
approval. In further support of the addition of SMA
to the RUSP, we report here guidelines of the SMA
NBS Multidisciplinary Working Group describing a
recommended treatment algorithm for those infants
identified as having a positive SMA newborn screen.
MATERIALS AND METHODS
SMA NBS multidisciplinary working group and
mission
The SMA NBS Multidisciplinary Working Group,
supported by a major patient advocacy group,
CureSMA, brought together clinicians and geneti-
cists with SMA expertise and patient advocacy
representatives to formulate a treatment algorithm for
individuals who have a positive SMA NBS test. The
working group consisted of a total of 15 members, five
of whom were organizing members, and 13 of whom
participated in voting. All working group members
participated voluntarily without compensation.
Achieving consensus through the delphi
technique
The working group employed a modified version of
the Delphi technique [30, 31] to reach consensus on
treatment guidelines. Data was collected using mul-
tiple iterative rounds [32] of an online survey. The
sequentialsurveysstartedwithafewbroaderquestions
that then motivated more specific questions related
to SMA treatment. Voting members answered survey
questions anonymously by choosing from a selec-
tion of responses. Following each survey, the group
response was reported back to the voting members.
During this discussion, voting members considered
whether to keep their original answers or change their
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opinions after seeing the overall group’s response.
An expert in the Delphi process served as a neu-
tral non-voting, third party member who moderated
discussions and had no stake in the decisions made.
This technique’s advantages include allowing vot-
ing members to provide their opinions anonymously,
without undue influence from more outspoken indi-
viduals within the group. This method allowed for
easy identification of topics for which the working
group did not initially reach consensus for further
examination. Another advantage of using this tech-
nique is the ease in using online tools that allow
global communication among physically distant vot-
ing members. Consequently, the Delphi method has
been increasingly used to reach consensus in many
fields, including education, medicine, and research
[33]. In order to achieve consensus on the treatment
algorithm and SMN-up-regulating therapy guide-
lines, four conference calls were held following
administration of the online surveys, in addition to
a final live polling to address outstanding questions.
RESULTS
Treatment algorithm for SMN-up-regulating
therapies
SMA has multiple genotypes and associated phe-
notypes, resulting in a spectrum of severity that may
include some asymptomatic individuals at its mildest,
albeit rarest, end. The first question to be addressed
was thus directed to which screen-identified SMA
individuals should be treated immediately with FDA-
approved therapies in the context of NBS, and which
should be monitored carefully with treatment initi-
ated later in life. This is of critical importance, as
some genotypes of SMA are imminently life threat-
ening without treatment.
The working group first developed a treatment
algorithm for the administration of an SMN-up-
regulating treatment based upon genotype following
a positive NBS result (Fig. 1). The initial decisions
for this algorithm were based on the correlation of
SMN genotype to phenotype across multiple studies.
SMA types 1 and 2 represent a large majority of SMA
cases and account for the bulk of those who screen
positive for SMA and have three or fewer copies of
SMN2 [11, 13, 15]. The working group unanimously
recommends immediate treatment for these individ-
uals to achieve a maximal response to treatment, as
supported by the strong positive results arising from
pre-symptomatic infants in the NURTURE trial for
individuals predicted to manifest SMA by qualifying
genotype who have either two and three copies of
SMN2 [26].
Recommendation for treatment of individuals who
screen positive for SMA and have low (one copy)
or high (four or more copies) SMN2 copy number
is more complicated, and summarized in Table 2
and Table 3. The working group recognizes that the
Fig. 1. SMA Newborn Screening Treatment Schematic for SMN-Up-Regulating Therapy. SMA=spinal muscular atrophy; SMN=survival
motor neuron.
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Table 2
Summary of working group’s voting responses concerning tests used to monitor patients with ≥4 SMN2 copies for whom treatment is not
initiated immediately
Survey Question Possible Responses Group Voting (%)
When thinking about patients with four SMN2 copies, what is the greater risk? (N= 9 voting members)
Not treating the child early enough who then develops symptoms, which may be more refractory to treatment
at that point
56
Treating the child who is subjected to the risks and burden of treatment and yet might not have exhibited signs
of SMA for many years
44
As a group developing a treatment algorithm for infants with SMA identiﬁed through NBS, do you feel we
should provide: (N= 9 voting members)
A prescriptive recommended battery of tests/evaluations with changes or early plateau values that would
trigger a recommendation of treatment
11
A list of possible appropriate tests where a change on any would allow informed clinical judgment to trigger
a recommendation of treatment
89
Which of the following would you recommend as follow-up testing/assessment in patients not initially treated,
assuming the patient was the correct age for the test? (N= 9 voting members)
Motor Function Scales 0
Myometry 0
EMG 0
CMAP 0
Physical Assessment, including reflexes 0
Any of the following 100
What level of change/results on an EMG should cause initiation of treatment? (N= 9 voting members)
Any active or chronic neurogenic change 100
Abnormal spontaneous activity in one proximal and one distal muscle 0
Abnormal spontaneous activity in two different muscle groups 0
Abnormal spontaneous activity in two limbs and an axial region 0
Any abnormal spontaneous activity/fibrillations 0
What level of change/results on a CMAP test should cause initiation of treatment? (N= 9 voting members)
Other (please specify) 0
20% decrease in amplitude from a prior test of that child 0
10% decrease in amplitude from a prior test of that child 0
20% below normative values for an age-matched child 0
Below normative values for an age-matched child 100
What level of change/results on a physical exam should cause initiation of treatment? Please select all
applicable choices. (N = 9 voting members)
Loss of reflexes 0
Weakness in trunk right/derotation 0
Proximal weakness defined as developmentally appropriate 0
Regression in ability to perform motor milestones 0
Failure to meet developmental motor milestones 0
All of the above 100
What level of otherwise unexplained decline or early plateau in age appropriate motor function assessments
(e.g., Bayley Scales, Hammersmith scales, CHOP INTEND, 6MWT, and WHO motor milestones) should
cause a recommendation of treatment? (N= 9 voting members)
A. A failure to gain motor functions with age in keeping with normal development 0
B. A drop in total score 0
Either A or B 100
Physicians should instructs parents/caregivers to contact them immediately if they see any of the following:
(N= 9 voting members)
Significant change in child’s movement, feeding, or breathing pattern during time of illness 100
Observed abdominal breathing 89
Failure to gain weight appropriately 89
Change in voice/weak cry 100
Increased fatigue without increased activity 100
Trouble feeding in young children or infants 100
Decline or loss of function in previously attained motor ability or failure to show progress in expected motor ability 100
CHOP INTEND = Children’s Hospital of Philadelphia Infants Test of Neuromuscular Disorders; CMAP = compound muscle action potential;
EMG = electromyograph; N = number of voting members; NBS = newborn screening; SMA = spinal muscular atrophy; SMN = survival motor
neuron; 6MWT = six-minute walk test; WHO = World Health Organization.
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majority of infants with SMA who have one copy of
SMN2 will be symptomatic at birth [34]. In this case,
the consensus is to defer to the attending physician to
determine if the infant and family would benefit from
treatment given his or her current disease state. In the
rare event that an SMA infant with one copy of SMN2
is truly pre-symptomatic, the strong consensus is that
the infant should be treated immediately. The work-
ing group was evenly divided as to whether infants
with four SMN2, as identified by NBS, should be
treated immediately or instead screened carefully for
the first signs of mild symptoms to initiate treatment
(n = 13). The committee did reach consensus that
patients with more than 4 copies should not be treated
immediately but screened carefully for the first pre-
sentation of symptoms. Recommendations were then
developed for what screens and tests should be care-
fully monitored (Table 3) and how often they should
occur to determine when treatment should be initiated
in infants and children undergoing watchful waiting.
Guidelines for follow up of follow up of infants
identiﬁed as having SMA with four copies of
SMN2
The following treatment recommendations are
intended to advise the follow-up and initiation of
an SMN-up-regulating therapy in infants and chil-
dren with four or more copies of SMN2, who are not
immediately treated with a FDA-approved disease
modifying therapy for SMA. These recommenda-
tions are intended as guidelines only. The working
group reached full consensus that the attending physi-
cian’s clinical judgment, as well as the patient’s
and/or the patient’s family’s wishes, should be the
deciding factor on when to initiate treatment (n = 13).
In patients with fewer than four copies of SMN2, it
should be noted that disease onset would be expected
to be more rapid and/or severe: deferring treatment
is not recommended for these patients, and thus the
following guidelines would not apply to such cases.
GUIDELINE NO. 1: FOR THOSE
PATIENTS IN WHOM TREATMENT IS
NOT INITIATED IMMEDIATELY,
ROUTINE FOLLOW-UP CARE SHOULD
IDEALLY BE PROVIDED BY A
NEUROMUSCULAR SPECIALIST
Given the options of a pediatrician, a neuromus-
cular specialist, and a general child neurologist, the
working group reached full consensus that a neu-
romuscular specialist would be able to provide the
best routine follow-up care in individuals with four
or more SMN2 copies (n = 9). A pediatrician’s exper-
tise in child healthcare may be broad and not cover
the unique features of a rare neuromuscular dis-
order, while a general child neurologist may not
specialize in the role of the neuromuscular system
in the patient’s symptomatology and diagnosis or
have the knowledge to administer the specific tests
being recommended here. The working group also
acknowledges that it is typically considered standard
practice through NBS programs to refer patients to
a geneticist, and this would also be advised in all
cases of SMA detected through NBS. A neuromuscu-
lar specialist would have the deepest knowledge of the
clinical manifestations of SMA in order to detect the
earliest symptomatology, in addition to experience
with administering the highly sensitive assessments
of motor neuron function and SMA specific motor
function. This recommendation is offered knowing
that not all patients live in communities with easy
access to a neuromuscular specialist.
GUIDELINE NO. 2: INFANTS IDENTIFIED
AS HAVING FOUR OR MORE COPIES OF
SMN2 SHOULD BE REFERRED TO
SOMEONE WHO CAN IDENTIFY THEIR
EXACT COPY NUMBER
Currently, not all commercial laboratories distin-
guish SMN2 copy number precisely at four or greater
copies, reporting those cases as “≥4 SMN2 copies”.
Given this imprecision, about 89% of the working
group (n = 9 [voting members]) felt that determining
the patient’s exact copy number would allow for a
more informed prediction of when disease symptoms
may appear. In addition, the working group discussed
the importance of checking for certain known disease
modifying mutations, such as the SMN2 c.859G>C
mutation in exon 7. This rare variant regulates the
splicing of SMN2 pre-mRNAs such that a greater
proportion of SMN2 transcripts contain exon 7,
resulting in a milder phenotype [35–37]. Generally,
because SMN2 copy number is a strong predictor
of disease severity, the group felt that identifying
the exact copy number, if that was not originally
provided, would greatly help inform an attending
physician in the best approach to monitor the patient’s
disease progression, as well as provide the best testing
strategies and follow-up care possible. In cases iden-
tified as having ≥4 SMN2 copies, there is no specific
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Table 3
Summary of tests used to monitor patients with ≥4 SMN2 copies for whom treatment is not initiated immediately
Test or Outcome Measure Level of Change/Results Which Would Prompt Initiation of Treatment Appropriate Age
of Patient for Test
EMG/nerve conduction Any active or chronic neurogenic change All
CMAP Below normative values for an age-matched child All
Myometry Decrease in extent of muscle contraction ≥4 years
Physical Exam/Reflexes Any of the following: loss of reflexes, failure to meet or regression in
ability to perform motor milestones, proximal weakness, and weakness
in trunk righting/de-rotation
All
CHOP INTEND A failure to gain motor functions with age in keeping with normal
development or a drop in total score from previous assessment
Infants
HINE A failure to gain motor functions with age in keeping with normal
development or a drop in total score from previous assessment
Infants
Hammersmith Functional
Motor Scale – Expanded
A failure to gain motor functions with age in keeping with normal
development or a drop in total score from previous assessment
≥2 years
6MWT A failure to gain motor functions with age in keeping with normal
development or a drop in total score from previous assessment
≥5 years
Bayley Scales of Infant and
Toddler Development
A failure to gain motor functions with age in keeping with normal
development or a drop in total score from previous assessment
Infants/Toddlers
(Recommended 1 to 42 months)
CHOP INTEND = Children’s Hospital of Philadelphia Infants Test of Neuromuscular Disorders; CMAP = compound muscle action potential;
EMG = electromyograph; HINE = Hammersmith Infant Neurological Exam; SMN2 = spinal motor neuron 2; 6MWT = six-minute walk test.
urgency to confirm exact copy number in a reference
laboratory, as these patients present with less rapid
disease progression than those with three or fewer
SMN2 copies.
GUIDELINE NO. 3: FOR THOSE
PATIENTS IN WHOM TREATMENT IS
NOT INITIATED IMMEDIATELY,
ROUTINE FOLLOW-UP CARE SHOULD
IDEALLY OCCUR EVERY THREE TO SIX
MONTHS UNTIL THE PATIENT REACHES
TWO YEARS OF AGE AND EVERY SIX TO
12 MONTHS THEREAFTER
The working group reached full consensus (n = 9
[voting members]) that a higher frequency of visits
early on is essential. This was recommended to ensure
the detection of any rare cases of children with a
severe SMA type 1 or 2, who have four or more copies
of SMN2. While a type 1 or 2 phenotype arising from
a genotype of four or more SMN2 copies is very rare,
the group agreed that due to the rapid progression
and severe morbidity of these types of SMA, ear-
lier more frequent monitoring to ensure that the child
does not have a more severe form of disease. Once the
child reaches two years of age having achieved motor
milestones, an early severe form of SMA can be con-
sidered excluded and the follow-up frequency can be
reduced, as less severe forms of disease are known
to have later onset and slower functional decline.
Therefore, a diminishing frequency algorithm for
follow-up visits is recommended, as frequency of
visits should correlate with the predicted severity of
the disease that drops as a function of age of onset.
Such an algorithm also provides parents and care-
givers flexibility in terms of the burden of follow-up
visits, while also attempting to minimize treatment-
related risks in a child with less severe SMA. The
schedule balancing these concerns can be modified
by caring physicians in the context of individual
circumstances.
GUIDELINE NO. 4: ASSUMING THE
PATIENT IS THE APPROPRIATE AGE
FOR A SPECIFIC TEST, THE
FOLLOWING ARE RECOMMENDED AS
FOLLOW-UP ASSESSMENTS IN
PATIENTS NOT INITIALLY TREATED:
ELECTROMYOGRAPHY (EMG),
COMPOUND MUSCLE ACTION
POTENTIAL (CMAP) MONITORING,
MYOMETRY, PHYSICAL
EXAMINATIONS, AND MOTOR
FUNCTION SCALES
The working group reached full consensus (n = 9
[voting members]) that EMG, CMAP monitoring,
myometry, physical examinations, and motor func-
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tion scales are each of potential value in follow-up
visits for children not initially treated (Table 2). The
group recommended a variety of tools to use for
assessment, knowing these tests will vary in avail-
ability, physician expertise and preference, and the
patient’s ability, based on age, to participate. This
allows for the inclusion of assessments that show
the highest sensitivity toward early changes in pre-
symptomatic children, like CMAP and EMG, in
addition to the utilization of physical assessments
and motor function scales that are less specialized,
require less skill, and are more broadly utilized across
clinical practices. It should also be noted that not
all of these assessments are appropriate for all age
ranges, and that tests should be carefully selected
based on the age of the patient. The working group’s
recommendation was that a change on any of these
assessments could be used as the basis to initiate
treatment.
The following sections outline guidelines for the
amount of change on each of the assessments that
is recommended to trigger initiation of treatment in
pre-symptomatic children with four or more SMN2
copies.
Any active or chronic neurogenic change in EMG
recordings
The working group reached full consensus (n = 9
[voting members]) that any active or chronic neu-
rogenic change in EMG recordings should prompt
initiation of treatment. EMG can detect neurogenic
changes in muscles and hence can be used to monitor
motor neuron or motor unit health in SMA patients
[38]. Due to the high sensitivity of this assessment,
any neurogenic change can indicate denervation of
muscle fibers and warrants further examination and
treatment in a patient with a known SMA genotype.
However, the working group also acknowledges vari-
ability in individual sites’ experience and comfort
with EMG in children. For example, the burden of
sedating a patient, based on the age of the child,
in regards to the frequency and use of EMG as an
assessment for monitoring for onset of disease must
be balanced.
Below normative values on a CMAP test for an
age-matched child
Similar to EMG, the working group reached full
consensus (n = 9 [voting members]) that CMAP
amplitudes that are below normative values for an
age-matched child should initiate treatment. As a
reliable electrophysiological measure of muscle func-
tion in SMA patients [39], this assessment is also
highly sensitive and an early indicator of disease
onset in a pre-symptomatic child. Many voting mem-
bers also felt that any drop in CMAP amplitudes
from a prior test of that individual should trigger
initiation. Due to the challenging technical nature
of these electrophysiological assessments, the guid-
ance for these two assessments (EMG and CMAP)
is not to look for a particular percentage change but
rather for any results below normative values in an
age-matched child. The working group is aware that
a threshold determination of the difference needed
to be meaningful is not available, and likely dif-
fers between institutions. This determination is thus
left to the discretion of the consulting neuromuscular
specialist.
Decrease in extent of muscle contraction as seen
in myometric measures
The working group acknowledges that there is
not a large body of evidence on normative values
for myometric measures in SMA patients. Thus,
the working group reached full consensus (n = 9
[voting members]) that any clinically meaningful
myometric changes [40] that indicate reduced mus-
cle force should initiate treatment. When considering
age appropriateness of this test, it should be noted
that this test is not recommended for children under
the age of 5 years. Additionally, the group acknowl-
edges that myometric testing can be technically
challenging in children given limited cooperation
and need for specialized equipment. Given these
difficulties, the working group noted the benefit of
coupling myometry evaluation with other physical
and electrophysiological examinations as part of a
comprehensive, watchful waiting regimen.
Changes in physical examinations, including loss
of reﬂexes, failure to meet or regression in ability
to perform motor milestones, proximal weakness,
and weakness in trunk righting/de-rotation
The working group reached full consensus (n = 9
[voting members]) that loss of previously identi-
fied tendon reflexes, failure to meet, or regression
in the ability to perform motor milestones, proxi-
mal weakness, and weakness in trunk righting or
de-rotation were all important physical examination
findings that should initiate treatment. Such changes
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are relatively straightforward and easily identified by
both neuromuscular specialists and general physi-
cians alike. These measures are generally accessible
without specialized equipment, and the assessments
are non-invasive and can easily be done in an office
setting, thus allowing for a broader application across
all communities. These assessments may, however,
be less sensitive to the early changes that develop
in early symptomatic SMA. The working group
recommends that these assessments accompany the
more sensitive electrophysiological tests as part of
a comprehensive follow-up.
A failure to gain motor function with age in
keeping with normal development or a drop in
total score in motor function assessments
The working group recommends that either a fail-
ure to gain age-appropriate motor function or a drop
in total score of in any motor function assessment
should trigger the initiation of treatment. When think-
ing about the appropriate assessment for an individual
patient, the working group advises that the age of the
patient (Table 3), along with physician’s own famil-
iarity with the administration of the assessment be
considered to allow for the most accurate and sensi-
tive monitoring. The following briefly describes the
motor function assessments considered by the work-
ing group for use in SMA patients.
The Children’s Hospital of Philadelphia Infant Test
of Neuromuscular Disorders (CHOP INTEND) was
initially developed to assess motor skills in infants
with SMA type 1 with a mean age of 11.5 months. The
assessment includes 16 items selected by an expert
panel and scored from a range of 0 (no response) to
4 (complete response) comprising a 64-point scale.
The items include both active, spontaneous move-
ments as well as elicited, reflex movements. As it
does not include respiratory or feeding behaviors, the
CHOP INTEND is both easy and quick to adminis-
ter and is well tolerated by infants [41]. Because this
assessment was designed for SMA type 1 infants with
severe muscle weakness, it is only recommended for
patients ages birth to two years of age. In addition,
asymptomatic children within this age range may
reach a ceiling prior to age two.
The HINE consists of 37 items, divided into three
sections. The first section contains 26 items assess-
ing cranial nerve function, movements, muscle tone,
posture, and reflexes. The second section includes
eight items assessing motor function development,
and lastly, the third section contains three items for
the assessment of behavioral state. All items may be
scored individually or added together to generate a
global score, providing a useful quantitative measure
of motor development [24]. This assessment is rela-
tively user-friendly and can be utilized in both clinical
and research settings with less technical skill required
and is recommended for infants under the age of two
years.
The Hammersmith Functional Motor Scale –
Expanded (HFMSE) is an SMA-specific scale of
motor function, including a 13-item expansion mod-
ule added to the original HFMS. The HFMS assesses
motor skills using 20 items scored on a 3-point Lik-
ert scale. Though it is easy to administer, requires
minimal equipment and technical skills, and is repro-
ducible, the range of skills that can be examined in
a patient (independent sitting to taking four steps) is
limited and can cause a ceiling effect in higher func-
tioning SMA patients. Thus, the HFMSE was created
to assess more detailed aspects of certain motor skills,
including lying supine; high and half kneeling; going
from standing to squatting; and standing while hold-
ing one rail and walking up steps. Such items were
validated as showing clinically meaningful changes
in patients with later-onset SMA types 2 and 3 [42].
Consequently, this assessment is recommended for
children two years of age and older who are able to
perform such activities.
The 6-minute walk test (6MWT) is easy and safe
to administer and is well-tolerated by most patients.
Originally used to assess functional capabilities in
adult heart and lung disease patients, it has since
been modified to assess walking abnormalities in
neuromuscular disorders. Further modifications have
allowed for its adaptation to children for the assess-
ment of gait abnormalities [43]. This assessment is
recommended for children five years of age and older,
for which normative values are available.
The Bayley Scales of Infant and Toddler Develop-
ment are individually administered instruments used
primarily to assess the development of infants and
toddlers between the ages of 1 and 42 months. These
measures consist of a series of developmental play
tasks that take between 45–60 minutes to adminis-
ter and derive a developmental quotient (DQ) rather
than an intelligence quotient (IQ). Raw scores of
successfully completed items are converted both to
scale scores and to composite scores, which are then
used to determine the child’s performance compared
with norms taken from typically developing children
of their age (in months). The most recent edition,
the Bayley-III has three main subtests: the Cogni-
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tive Scale, the Language Scale, and the Motor Scale
[44]. These scores are largely used for screening and
identifying the need for further observation and inter-
vention in infants who score outside the normative
values. The Bayley has been validated in many stud-
ies of children with motor delay in the first years of
life [45] and was used in a recent SMA clinical trial
assessing an SMN replacement therapy [19].
GUIDELINE NO. 5: PHYSICIANS SHOULD
INSTRUCT PARENTS/CAREGIVERS TO
CONTACT THEM IMMEDIATELY IF
THEY SEE ANY OF THE FOLLOWING
• Significant change in child’s movement, feed-
ing, or breathing pattern
• Change in voice/weak cry
• Increased fatigue without increased activity
• Trouble feeding in young children or infants
• Decline or loss of function in previously attained
motor ability or failure to show progress in
expected motor ability
• Abdominal breathing
• Failure to thrive
The working group recommended development
of materials or a written checklist that parents or
caregivers would utilize at home to aid in the
surveillance of potential SMA signs triggering imme-
diate re-evaluation. The working group reached full
consensus (n = 9 [voting members]) that the obser-
vation between clinical visits of any of the first
five manifestations of SMA listed above should trig-
ger patients and caregivers to immediately contact
their neuromuscular specialist or attending physician.
Consensus was not reached on whether the last two
manifestations should be included in such materi-
als, not because they are not important symptoms of
SMA, but rather that several voting members felt that
patients should be identified well before their mani-
festation. Overall, these seven items are overt signs
of SMA that traditionally have been used to diagnose
the most severe form of the disease during infancy.
SMA is often first detected in patients during the
course of an acute illness in the hospital or clinic set-
ting after presenting with these symptoms or those of
an associated respiratory illness. The working group
anticipates that in the context of NBS, pharmacolog-
ical drug intervention should be initiated well before
the onset of these signs and symptoms if clinicians
are successful in their surveillance. Thus, the voting
members recommended that parental observation of
any of these should prompt immediate re-evaluation
of the patient.
This final recommendation underlies the critical
need for educational materials to be provided to all
parents whose children are diagnosed with SMA
via NBS, as the disease course will be different
than children diagnosed with SMA after symptom
presentation.
DISCUSSION
In summary, the SMA NBS Multidisciplinary
Working Group reached consensus on a variety of
topics related to the follow-up care and treatment of
SMA patients. The working group acknowledges that
the vast majority of SMA patients will have three
or fewer copies of SMN2. Lower SMN2 copy num-
ber correlates with increased disease severity, rapid
disease onset, and poor prognosis [11, 13, 15], caus-
ing the working group to recommend these patients
be treated immediately. In addition, there is clinical
trial data supporting the enhanced efficacy of pre-
symptomatic treatment in patients with two and three
copies of SMN2.
The working group did not reach consensus on
the immediate treatment of patients with four or
more SMN2 copies, as these patients do not typically
present as early or with as severe forms of SMA as
patients with a lower copy number. Given that the
voting members were split on their responses to this
question (Table 2), they developed an algorithm for
an effective means of surveillance in patients with
four or more copies of SMN2 who may not be treated
immediately. In doing so, they had to balance the
risks of treatment and the demands of follow-up vis-
its, when symptoms may not present for years, versus
not treating the child early enough to achieve maxi-
mal benefit from a pharmacological drug treatment.
Thus, the group recommended that follow-up visits
should ideally happen every three to six months until
the patient reaches two years of age and every six to
12 months thereafter.
Given that very few patients with four or
more copies of SMN2 have been followed pre-
symptomatically, the protocol for following such
patients follows recommendation of clinical acumen
rather than a data-driven path. This group of experts
recommended that in ideal situations, a neuromus-
cular specialist would monitor patients for follow-up
care, including EMG, CMAP, myometry, physical
examinations, and age-appropriate motor function
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scales. The use of a variety of assessments allows the
physician more latitude and reliance on clinical judg-
ment. In addition, in regions where neuromuscular
experts are not readily available, not all assessments
may be easily or reliably administered. It is hoped
that application of NBS will generate data about the
full range of phenotypes associated with individuals
identified to have SMA with four or more copies of
SMN2, and thereby help refine these recommenda-
tions made largely from arguments of plausibility
even further.
Strong evidence warrants the need for early
identification and treatment of SMA children. The
co-identification of SMN1 deletion and SMN2 copy
number often allows clinicians to predict the SMA
type and corresponding disease severity in order to
select the best timing for FDA-approved drug treat-
ments for SMA. The guidelines noted here were
created by the SMA NBS Multidisciplinary Working
Group to serve as recommendations for which infants
identified through NBS should be immediately
treated with SMN-up-regulating therapy. Addition-
ally, the guidelines provide recommendations for
a surveillance regimen for infants not immediately
treated. The working group acknowledges that the
advent of new FDA-approved therapies in the future
will prompt the need for additional consideration
by both physicians and patients alike, as each drug
will present unique risks, burdens, and benefits to
the patient, including comparative level of efficacy,
route of administration, frequency of administration,
known side effect profile, and time to clear the drug
in cases of an adverse event. Finally, given univer-
sal NBS has already begun in several states in the
US, both the collection of natural history data and
the assessment of long-term term cost effectiveness
of NBS for SMA will be critical to further inform
treatment and care of SMA patients.
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